Bimatoprost: mechanism of ocular surface hyperemia associated with topical therapy.

No abstract is available for this paper.

• Publication year

  2006

• Venue

  Cardiovascular Drug Reviews

• Publication date

  2006-06-07

• Fields of study

  Medicine

• Identifiers
  DOI 10.1111/J.1527-3466.2005.TB00168.XPMID 16252016
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Bimatoprost: a novel antiglaucoma agent.

  2006cited by this paper
• In vitro study of inflammatory potential and toxicity profile of latanoprost, travoprost, and bimatoprost in conjunctiva-derived epithelial cells.

  2005cited by this paper
• Studies using isolated uterine and other preparations show bimatoprost and prostanoid FP agonists have different activity profiles

  2005cited by this paper
• Bimatoprost and prostaglandin F(2 alpha) selectively stimulate intracellular calcium signaling in different cat iris sphincter cells.

  2005cited by this paper
• Conjunctival Hyperemia Related to Bimatoprost Treatment is Not Associated with Signs of Inflammation

  2004cited by this paper
• Two-year double-masked comparison of bimatoprost with timolol in patients with glaucoma or ocular hypertension.

  2004cited by this paper
• Conjunctival hyperemia associated with bimatoprost use: a histopathologic study.

  2004cited by this paper
• Mechanism of ocular hypotensive action of bimatoprost (Lumigan) in patients with ocular hypertension or glaucoma.

  2004cited by this paper
• Pharmacological Characterization of a Novel Antiglaucoma Agent, Bimatoprost (AGN 192024)

  2003cited by this paper
• A comparison of latanoprost, bimatoprost, and travoprost in patients with elevated intraocular pressure: a 12-week, randomized, masked-evaluator multicenter study.

  2003cited by this paper
• Conjunctival hyperemia in healthy subjects after short-term dosing with latanoprost, bimatoprost, and travoprost.

  2003cited by this paper
• Endothelial nitric oxide synthase: the Cinderella of inflammation?

  2003cited by this paper
• Multicenter, open-label evaluation of hyperemia associated with use of bimatoprost in adults with open-angle glaucoma or ocular hypertension

  2003cited by this paper
• Protective role of endothelial nitric oxide synthase

  2003cited by this paper
• A six-month randomized clinical trial comparing the intraocular pressure-lowering efficacy of bimatoprost and latanoprost in patients with ocular hypertension or glaucoma.

  2003cited by this paper
• Effect of bimatoprost on patients with primary open-angle glaucoma or ocular hypertension who are nonresponders to latanoprost.

  2003cited by this paper
• Ocular Surface Changes Associated with the Use of Bimatoprost 0.03

  2003cited by this paper
• A six-month randomized clinical trial comparing the intraocular pressure-lowering efficacy of bimatoprost and latanoprost in patients with ocular hypertension or glaucoma

  2003cited by this paper
• Efficacy of bimatoprost in glaucoma and ocular hypertension unresponsive to latanoprost

  2002cited by this paper
• The role of nitric oxide in ocular surface cells.

  2002cited by this paper
• One-year, randomized study comparing bimatoprost and timolol in glaucoma and ocular hypertension.

  2002cited by this paper
• Bimatoprost and travoprost: a review of recent studies of two new glaucoma drugs.

  2002cited by this paper
• Prostanoid FP receptor mediated, endothelium dependent vasodilatation and the ocular surface hyperemic response to PGF2 alpha and related compounds.

  2002cited by this paper
• The pharmacology of bimatoprost (Lumigan).

  2001cited by this paper
• Efficacy and safety of bimatoprost in patients with elevated intraocular pressure: a 30-day comparison with latanoprost.

  2001cited by this paper
• Role of nitric oxide in the control of ocular blood flow.

  2001cited by this paper
• Microvascular effects of selective prostaglandin analogues in the eye with special reference to latanoprost and glaucoma treatment.

  2000cited by this paper
• Functional role of nitric oxide in regulation of ocular blood flow.

  1999cited by this paper
• Effects of Prostaglandin E2, F2α, and Latanoprost Acid on Isolated Ocular Blood Vessels In Vitro

  1998cited by this paper
• Effect of nimesulide and indomethacin on contractility and the Ca2+ channel current in myometrial smooth muscle from pregnant women

  1998cited by this paper
• Mediation of prostaglandin f2 alpha-induced ocular surface hyperemia by sensory nerves in rabbits.

  1997cited by this paper
• Mechanism of prostaglandin E2-, F2alpha- and latanoprost acid-induced relaxation of submental veins.

  1997cited by this paper
• Identification of a prostanoid FP receptor population producing endothelium‐dependent vasorelaxation in the rabbit jugular vein

  1995cited by this paper
• Role of Nitric Oxide in PGF2a-Induced Ocular Hyperemia

  1994cited by this paper
• Role of nitric oxide in PGF2 alpha-induced ocular hyperemia.

  1994cited by this paper
• Characterization of three inhibitors of endothelial nitric oxide synthase in vitro and in vivo

  1990cited by this paper
• Histamine contraction of isolated human airway muscle preparations: role of prostaglandins.

  1986cited by this paper
• Effect of nicotine on prostacyclin formation in rat aorta.

  1983cited by this paper
• ANGIOTENSIN RECEPTORS IN BOVINE UMBILICAL ARTERY AND THEIR INHIBITION BY NONSTEROIDAL ANTI‐INFLAMMATORY DRUGS

  1981cited by this paper
• The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine

  1980cited by this paper
• PROSTAGLANDIN PRODUCTION BY RABBIT ISOLATED JEJUNUM AND ITS RELATIONSHIP TO THE INHERENT TONE OF THE PREPARATION

  1976cited by this paper
• EFFECT OF INDOMETHACIN AND PROSTAGLANDIN ON THE SMOOTH MUSCLE CONTRACTING ACTIVITY OF ANGIOTENSIN AND OTHER AGONISTS

  1976cited by this paper
• THE EFFECT OF INDOMETHACIN ON THE RELEASE OF PROSTAGLANDIN E2 AND ACETYLCHOLINE FROM GUINEA‐PIG ISOLATED ILEUM AT REST AND DURING FIELD STIMULATION

  1974cited by this paper
• Mechanism of the inhibitory action of indomethacin on smooth muscle

  1971cited by this paper

• Quantifying latanoprost-induced conjunctival hyperemia by anterior segment optical coherence tomography angiography.

  2025cites this paper
• Efficacy and safety of prostaglandin drugs for elevated intraocular pressure: a Bayesian network meta-analysis

  2025cites this paper
• Outcome of combined trabeculectomy with cataract surgery in patients on prostaglandin analogs and aqueous suppressants

  2024cites this paper
• Clinical Efficacy of Topical Tacrolimus on Conjunctival Hyperemia Caused by Prostaglandin Analogues

  2022cites this paper
• Prevalence of Ocular Surface Disease and Associated Risk Factors in Glaucoma Patients: A Survey Study of Ophthalmologists

  2022cites this paper
• Remodeling of the Lamina Cribrosa: Mechanisms and Potential Therapeutic Approaches for Glaucoma

  2022cites this paper
• Ocular redness - II: Progress in development of therapeutics for the management of conjunctival hyperemia.

  2021cites this paper
• Effect and Safety of Travoprost 0.003% in Open Angle Glaucoma

  2021cites this paper
• Multiple drug delivery from the drug-implants-laden silicone contact lens: Addressing the issue of burst drug release.

  2020cites this paper
• Nonclinical Pharmacokinetic and Pharmacodynamic Assessment of Bimatoprost Following a Single Intracameral Injection of Sustained-Release Implants

  2020cites this paper
• Medical Management of Glaucoma

  2020cites this paper
• Factors Predetermining Increased Aqueous Humour Flare in Long-Term Glaucoma Treatment

  2020cites this paper
• Short-Term Effects of Different Types of Anti-Glaucoma Eyedrop on the Sclero-Conjunctival Vasculature Assessed Using Anterior Segment OCTA in Normal Human Eyes: A Pilot Study

  2020cites this paper
• Medical anti-glaucoma therapy: Beyond the drop.

  2020cites this paper
• Current and emerging fixed combination therapies in glaucoma: a safety and tolerability review

  2020cites this paper
• Distribution of 14C-Latanoprost Following a Single Intracameral Administration Versus Repeated Topical Administration

  2020cites this paper
• Profiling ocular surface responses to preserved and non‐preserved topical glaucoma medications: A 2‐year randomized evaluation study

  2020cites this paper
• Glaucoma Medications’ Effect on Ocular Surface

  2019cites this paper
• Episcleral Venous Pressure and the Ocular Hypotensive Effects of Topical and Intracameral Prostaglandin Analogs

  2019cites this paper
• Ocular Surface Changes in Prostaglandin Analogue-Treated Patients

  2019cites this paper
• Bimatoprost loaded microemulsion laden contact lens to treat glaucoma

  2019cites this paper
• Prostaglandin analogues and nitric oxide contribution in the treatment of ocular hypertension and glaucoma

  2019cites this paper
• Bimatoprost sustained‐release intracameral implant reduces episcleral venous pressure in dogs

  2018cites this paper
• Effect of topical ophthalmic latanoprost 0.005% solution alone and in combination with diclofenac 0.1% solution in healthy horses: a pilot study

  2017cites this paper
• Factors Related to Prostaglandin‐Associated Periorbitopathy in Glaucoma Patients

  2017cites this paper
• The exit strategy: Pharmacological modulation of extracellular matrix production and deposition for better aqueous humor drainage.

  2016cites this paper
• Chapter 6 – The Pharmacology of Prostaglandin F2α Ethanolamide and Bimatoprost Reveals a Unique Feedback Mechanism on Endocannabinoid Actions

  2015cites this paper
• Comparison of two- and three-times-daily topical ophthalmic application of 0.005% latanoprost solution in clinically normal dogs.

  2015cites this paper
• Diurnal Intraocular Pressure with Bimatoprost/Timolol Fixed Combination versus Latanoprost/Timolol Fixed Combination in Healthy Subjects

  2014cites this paper
• an observational study of bimatoprost 0.01% in patients on prior intraocular pressure-lowering therapy: the Canadian lumigan ® rC early analysis review (Clear) trial

  2014cites this paper
• Bimatoprost 0.01% vs bimatoprost 0.03%: a 12-month prospective trial of clinical and in vivo confocal microscopy in glaucoma patients

  2014cites this paper
• The impact of timolol maleate on the ocular tolerability of fixed-combination glaucoma therapies

  2014cites this paper
• Bimatoprost: a unique compound that in its nonhydrolyzed form is a prostamide and hydrolyzed form has prostaglandin receptor activity, for glaucoma and cosmetic indications

  2014cites this paper
• an observational study of bimatoprost 0.01% in patients on prior intraocular pressure-lowering therapy: the Canadian lumigan ® rC early analysis review (Clear) trial

  2014cites this paper
• Therapeutic uses of prostaglandin F(2α) analogues in ocular disease and novel synthetic strategies.

  2013cites this paper
• Study Design and Methodologies for Evaluation of Anti-glaucoma Drugs

  2013cites this paper
• An observational study of bimatoprost 0.01% in treatment-naïve patients with primary open angle glaucoma or ocular hypertension: the CLEAR trial

  2012cites this paper
• Topical application of 0.005% latanoprost increases episcleral venous pressure in normal dogs.

  2012cites this paper
• Bimatoprost and Bimatoprost/Timolol Fixed Combination in Patients with Open-Angle Glaucoma and Ocular Hypertension

  2011cites this paper
• Long-term safety evaluation of bimatoprost ophthalmic solution 0.03%: a pooled analysis of six double-masked, randomized, active-controlled clinical trials

  2011cites this paper
• Efficacy and Safety of Switching from Topical Latanoprost to Bimatoprost in Patients with Normal-Tension Glaucoma

  2011cites this paper
• Clinical utility and differential effects of prostaglandin analogs in the management of raised intraocular pressure and ocular hypertension

  2010cites this paper
• Effects of topical administration of latanoprost, timolol, or a combination of latanoprost and timolol on intraocular pressure, pupil size, and heart rate in clinically normal dogs.

  2010cites this paper
• A randomized, controlled comparison of macroscopic conjunctival hyperemia in patients treated with bimatoprost 0.01% or vehicle who were previously controlled on latanoprost

  2010cites this paper
• In vivo comparative study of ocular vasodilation, a relative indicator of hyperemia, in guinea pigs following treatment with bimatoprost ophthalmic solutions 0.01% and 0.03%

  2010cites this paper
• Corneal Neovascularization and Ocular Irritancy Responses in Dogs Following Topical Ocular Administration of an EP4-Prostaglandin E2 Agonist

  2009cites this paper
• Bimatoprost-Induced Calcium Signaling in Human T-Cells does not Involve Prostanoid FP or TP Receptors

  2009cites this paper
• Role of prostaglandins and specific place in therapy of bimatoprost in the treatment of elevated intraocular pressure and ocular hypertension: A closer look at the agonist properties of bimatoprost and the prostamides

  2009cites this paper
• Role of prostaglandins and specific place in therapy of bimatoprost in the treatment of elevated intraocular pressure and ocular hypertension: A closer look at the agonist properties of bimatoprost and the prostamides

  2009cites this paper
• Managing refractory glaucoma with a fixed combination of bimatoprost (0.03%) and timolol (0.5%)

  2008cites this paper
• Efficacy and safety of bimatoprost/timolol fixed combination in the treatment of glaucoma or ocular hypertension

  2008cites this paper
• A multicentre evaluation of the effect of patient education on acceptance of hyperaemia associated with bimatoprost therapy for glaucoma or ocular hypertension

  2008cites this paper
• Recurrent serous macular detachment after topical ocular hypotensive medication

  2008cites this paper
• Side effects associated with prostaglandin analog therapy.

  2008cites this paper
• Meta-analysis of 13 randomized controlled trials comparing bimatoprost with latanoprost in patients with elevated intraocular pressure.

  2008cites this paper
• Fixed-combination and emerging glaucoma therapies

  2007cites this paper
• Bimatoprost/Timolol Fixed Combination: A 3-month Double-masked, Randomized Parallel Comparison to Its Individual Components in Patients With Glaucoma or Ocular Hypertension

  2007cites this paper
• Síndrome glaucomatosa em cães: Parte 2

  2007cites this paper
• Effects of topical administration of latanoprost, timolol, or a combination of latanoprost and timolol on intraocular pressure, pupil size, and heart rate in clinically normal dogs

  year unknowncites this paper
• Clinical Ophthalmology Dovepress Dovepress an Observational Study of Bimatoprost 0.01% in Patients on Prior Intraocular Pressure-lowering Therapy: the Canadian Lumigan ® Rc Early Analysis Review (clear) Trial

  year unknowncites this paper
• Effects of topical administration of latanoprost, timolol, or a combination of latanoprost and timolol on intraocular pressure, pupil size, and heart rate in clinically normal dogs

  year unknowncites this paper